Company / R&D Expense
BioLife Solutions, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$7.6M
FY2025
5-year range
$4.8M / $11.8M
FY2021-FY2025
Trend
+59.3%
vs FY2024
Sector context
#103 of 105
Health Care
What the data says
Among 105 Health Care companies, BioLife Solutions, Inc. is in the bottom 2% for r&d expense. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $8M.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +2.4%.
Improved from $6M to $8M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -4.4%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 105This company $7.6M Sector average $284.2M
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2025, r&d expense increased 59.3% year-over-year.
- Ranks #103 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.6M | +59.3% |
| FY2024 | $4.8M | -13.9% |
| FY2023 | $5.5M | -36.4% |
| FY2022 | $8.7M | -26.6% |
| FY2021 | $11.8M | +75.9% |
| FY2020 | $6.7M | +112.1% |
| FY2019 | $3.2M | +372.1% |
| FY2018 | $671.0K | -43.8% |
| FY2017 | $1.2M | -41.2% |
| FY2016 | $2.0M | +47.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026